HHS’ commitment to transparency
Executive Summary
Concerns about FDA's regulation of drug safety will not need a legislative fix, HHS Secretary Michael Leavitt told the Pharmaceutical Research & Manufacturers of America annual meeting in Washington, D.C. March 17. HHS hopes to use the Medicare program as one instrument to help improve data collection to support post-marketing surveillance, Leavitt said. He also stressed the importance of increasing the transparency of FDA's approach to drug safety issues. Leavitt's luncheon address was closed to the media...
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.